In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
A director at Pediatrix Medical Group Inc. sold 27,600 shares at 15.350USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Rating Action: Moody's upgrades Mednax's CFR to Ba3; rates new unsecured notes Ba3, outlook stable. Global Credit Research- 01 Feb 2022. New York, February 01, 2022-- Moody's Investors Service upgraded Mednax, Inc.' s Corporate Family Rating to Ba3 from B1 and Probability of Default Rating to Ba3-PD from B1-PD.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.. Global Credit Research- 06 Dec 2021. New York, December 06, 2021-- Moody's Investors Service has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit.
The independent financial analyst theScreener just lowered the general evaluation of MEDNAX (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date September 28, 2021, the closing price was USD 28.7...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Current market expectations for GTII are for profitability to reverse impressive gains, and growth to remain high but slow significantly. Markets expect UAFRS-based ROA (Uniform ROA or ROA') to drop from a forecasted 30% in 2021 to 17% going forward, with growth falling by more than half. However, the company is primed to ride the tailwinds of cannabis legalization, which may lead to the market opportunity for Green Thumb to more than triple in the coming years. On top of that, the company ha...
MEDNAX, Inc. (MD:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 17.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may be concerned about commercial and payer mix declines, the potential of their NightLight acquisition, and pandemic-related headwinds Specifically, management may lack confidence in their ability to mitigate revenue declines and meet EBITDA targets, and they may be concerned about...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.. Global Credit Research- 14 Jan 2021. New York, January 14, 2021-- Moody's Investors Service has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit.
Rating Action: Moody's confirms MEDNAX's B1 CFR, outlook positive. Global Credit Research- 18 Dec 2020. New York, December 18, 2020-- Moody's Investors Service confirmed MEDNAX, Inc.' s B1 Corporate Family Rating, the B1-PD Probability of Default Rating and the B1 unsecured global note ratings and changed the outlook to positive from rating under review.
CORPORATES CREDIT OPINION 16 September 2020 Update RATINGS MEDNAX, Inc. Domicile Sunrise, Florida, United States Long Term Rating B1 , Possible Upgrade Type LT Corporate Family Ratings Outlook Rating(s) Under Review Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Kailas
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.